Bone is a common metastatic site of cancer. Bone metastasis reduces life expectancy and results in serious symptoms and complications such as bone pain, pathological fractures, and spinal cord compression, decreasing quality of life by restricting sleep and mobility. Treatment for bone metastasis includes drugs (pure analgesics, hormones, cytotoxic chemotherapy, and bisphosphonates, among others), external radiation therapy, surgery, and radionuclide therapy using bone-targeting radiopharmaceuticals. Particulate radiation with α-or β-rays is used as a bone-targeting radiopharmaceutical in radionuclide therapy. β-Emitters have lower energy and a longer range than α-emitters and have less tumoricidal activity and deliver more radiation to adjacent normal tissue. Therefore, the main therapeutic effect of bone-targeting β-emitters such as 89 Sr-dichloride is bone pain palliation rather than enhanced survival. In contrast, α-emitters such as 223 Ra-dichloride have high energy and a short range, resulting in greater tumoricidal activity and less radiation damage to adjacent normal tissue. Treatment with bone-targeting α-emitters can improve survival and decrease bone pain. This review focuses on the principles and clinical utility of several clinically available bone-targeting radiopharmaceuticals in metastatic bone disease.
Introduction
Bone is a common metastatic site of cancer. The incidence of skeletal metastasis is highest in advanced breast or prostate cancer, followed by thyroid, kidney, and lung cancer. Bone metastasis reduces life expectancy and results in serious symptoms and complications such as bone pain, pathological fractures, and spinal cord compression, which decrease quality of life by restricting sleep and mobility. Therefore, appropriate treatment is essential [1, 2] .
Bone metastases are typically classified into osteolytic, osteosclerotic, or mixed, based on simple radiographic findings [1] [2] [3] . If bone resorption mainly occurs in relation to increased osteoclastic activity, it results in focal bone destruction, and the bone has an osteolytic appearance on simple radiographs. Osteolytic metastasis is commonly observed in patients with multiple myeloma, melanoma, or lung, thyroid, breast, renal, or gastrointestinal cancers. In contrast, if new bone formation is mainly due to increased osteoblastic activity, metastatic lesions have an osteosclerotic appearance on simple radiographs. Osteosclerotic metastasis is commonly observed in patients with prostate, lung, or breast cancer. However, these two bone processes usually occur simultaneously in affected bones. The type of bone metastasis usually does not affect the choice of treatment modality with the exception of bone-targeting radiopharmaceuticals.
Treatment options for bone metastasis include drugs (pure analgesics, hormones, cytotoxic chemotherapy, and bisphosphonates, among others), external radiation therapy, surgery, and radionuclide therapy using bonetargeting radiopharmaceuticals [1] [2] [3] [4] . Each treatment modality has specific clinical indications, advantages, and disadvantages. This review focuses on the principles and clinical utility of several clinically available bonetargeting radiopharmaceuticals.
Bone-Targeting Radiopharmaceuticals for Bone Metastasis
Requirements for optimal bone-targeting radiopharmaceuticals are: [5] (1) Selective uptake and prolonged retention in metastatic bones with a high metastatic-to-normal bone uptake ratio; (2) Rapid clearance from nonskeletal sites and fast excretion into urine or feces; (3) Biodistribution that can be estimated by imaging modalities such as bone scans; (4) Simple production process, good radiochemical stability, and clinical availability; (5) Cost-effectiveness; (6) Low toxicity and few side effects; (7) Radiation safety for patients and nuclear medicine staff; (8) Clinically proven therapeutic effects of reduced analgesic use and bone pain palliation and/or survival benefits.
Physical and radiation properties of several representative therapeutic bone-targeting radiopharmaceuticals are listed in Table 1 Ra-dichloride are β-emitters. β-Emitters have lower energy and a longer range than α-emitters and therefore have less tumoricidal activity and deliver more radiation to adjacent normal tissue than α-emitters. Therefore, the main therapeutic effect of bone-targeting β-emitters is bone pain palliation rather than survival. In contrast, α-emitters have a higher energy and shorter range than β-emitters and therefore have greater tumoricidal activity and deliver less radiation to adjacent normal tissue. With bone-targeting α-emitters, survival benefits are possible along with bone pain palliation. Several β-emitters with abundant γ-emission such as 188 Re-hydroxyethylidine diphosphonic acid  (HEDP),   153   Sm-ethylenediamine tetra methylene phosphonic acid (EDTMP),   117m   Sn-diethylenetriamine pentaacetic acid (DTPA), and   177 Lu-EDTMP can also be used for gamma camera imaging, which facilitates in vivo imaging for theranostics combined with tumor treatment (Fig. 1) .
Pain from bone metastasis is chronic. Underlying mechanisms of pain include neurochemical changes in expression of substance P, c-Fos, and dynorphin at the spinal cord level, central sensitization, peripheral sensitization, production of algogenic substances by tumor cells and inflammatory cells, sustained activation of osteoclasts, and nerve compression and injury caused by tumor growth [10] . Among these mechanisms, the cytocidal effects of particulate radiation on radiation-sensitive inflammatory cells such as lymphocytes appear to be most important for reducing bone pain because of the associated decrease in pain-related cytokines [9] [10] [11] [12] .
In general, bone-targeting radiopharmaceuticals have several advantages compared to other treatment modalities for symptomatic metastatic bone pain [5, 6] . Radionuclide therapy using bone-targeting radiopharmaceuticals is beneficial for diffuse bone pain caused by multiple metastases. Second, this therapy is appropriate for application in cases of poor response to other therapies or when there is concern about overuse of analgesics. Several factors should be taken into consideration when planning to use bonetargeting radiopharmaceuticals [5, 6] . Bone-targeting radiopharmaceuticals accumulate mainly in osteosclerotic, osteoblastic bone metastasis. They are therefore not suitable for treating osteolytic, osteoclastic bone metastasis. Furthermore, in metastatic bones vulnerable to fracture, local therapy such as surgery or radiation therapy should be performed prior to radionuclide therapy. There are several requirements for bone pain palliation by β-emitters [5, 6, 13] . First, osteoblastic metastasis must be confirmed by bone scintigraphy. Second, the pain should correlate with the sites of osteoblastic metastases. Third, renal function should not be impaired, and the patient should not be pregnant, breast-feeding, have spinal cord compression, impending bone fractures, or extensive bone metastasis (metastasis with a 'super scan' appearance). Recommended biochemical parameters of renal function are creatinine ≤ 180 μmol/l and/or glomerular filtration rate ≥ 30 ml/min. Fourth, patients should be hematologically stable. Relative contraindications include serum hemoglobin < 90 g/l, total white blood cell count < 3.5 × 10 9 /l, and platelet count < 100 × 10 9 /l. However, in some situations, a total white blood cell count ≥ 2.4 × 10 9 /l and platelet count ≥ 60 × 10 9 /l are acceptable. Finally, the life expectancy of patients should be more than 3 months [13] .
Although there are no definite differences in the efficacy of bone pain palliation among the various β-emitters available, the duration of response is longer for long-lived radioisotopes (i.e., 89 Sr-dichloride) than for short-lived isotopes (i.e., 186 Re-HEDP and 153 Sm-EDTMP) [13] . In responding patients, in cases of recurrent pain, retreatment can be effective and safe if hematological parameters have fully recovered, although the quality of response can decrease with treatments. The minimum interval should be of 8 weeks for 153 Sm-EDTMP, 6-8 weeks for 186 Re-HEDP, and 12 weeks for 89 Sr-dichloride [14, 15] . Clinical indications of representative therapeutic bone-targeting radiopharmaceuticals along with the current authority approval status are summarized in Table 2 .
P-Orthophosphate
32 P-orthophosphate is a reactor-produced, pure β-emitting, clinically available bone-seeking radionuclide that has been used to treat palliative bone metastasis since the 1950s [16] . It can be orally or intravenously administered at a single dose of 185-444 MBq or up to 888 MBq in multiple doses. About 85% of the administered dose is incorporated into hydroxyapatite in the bone matrix.
32 Porthophosphate is often given with an androgen such as testosterone to stimulate bone uptake in patients with metastasis from breast or prostate cancer [17] [18] [19] .
Response rates for bone pain palliation in prostate cancer are between 59% and 93% (overall 77%), and those in breast cancer are between 52% and 94% (overall 84%). However, no definite dose-response relationship has been established. Pain palliation typically occurs within 14 days, with a range of 2 days to 4 weeks. Mean reported duration of pain palliation from 32 P-orthophosphate is 5.1 ± 2.6 months, with the longest responses noted as 16.8 ± 9.4 months for multiple doses [19] .
As many as 50% of patients receiving both androgen and 32 P-orthophosphate experience a transient increase in pain (known as the Bflare phenomenon^). A major concern with 32 P-orthophosphate is hematological toxicity, including bone marrow suppression. Pancytopenia dose-dependently occurs around 4-5 weeks, with recovery by 6-7 weeks. Occurrence of acute leukemia after 32 P-orthophosphate therapy has been reported in addition to polycythemia vera. Grade 4 leukopenia and thrombocytopenia are rare [20] . However, due to the higher toxicity of 32 P-orthophosphate than other boneseeking therapeutic radiopharmaceuticals such as 89 Srdichloride, it is rarely used clinically for bone pain palliation and has not been officially approved by the US Food and Drug Administration (FDA) or Korean Ministry of Food and Drug Safety (MFDS) [21, 22] . 
Sr-Dichloride
Because 89 Sr is in the same periodic table of elements family as calcium, it localizes in bones, primarily in areas of high osteoblastic activity. The usual therapeutic dose is 148 MBq (4 mCi) or 1.48 MBq/kg (40 μCi/kg). After intravenous injection of 89 Sr as 89 SrCl 2 , 30-35% of the radiopharmaceutical binds to the hydroxyapatite bone matrix as a substitute for calcium for 10-14 days with 20% retention at 3 months. The remaining radiopharmaceutical is excreted by renal (80%) and fecal routes (20%) and has a biological half-life of 4-5 days [23] .
Response rates for bone pain palliation are between 60% and 90% (overall 76%), with complete pain relief in 5-20% of patients [20] [21] [22] [24] [25] [26] . Pain palliation occurs within 4-28 days, with a mean pain reduction duration of 3-6 months, up to 15 months. Retreatment for responders is possible at approximately 3-month intervals. Like 32 P-orthophosphate, the symptomatic flare phenomenon can occur in the first 1-5 days after administration, which predicts a good response.
Complete pain relief and myelosuppression show a doseresponse relationship [27, 28] . Hematological toxic effects are the most commonly observed side effects, with a decrease in white blood cell count of 11-65% occurring in 12-80% of patients [26] . The platelet count decreases by about 29% in 29-80% of patients, whereas the red blood cell count does not change significantly [26] . The nadir of leukopenia and thrombocytopenia is observed at 5-8 weeks after administration, and recovery is seen at 10-16 weeks [21, 22, [28] [29] [30] .
Clinical indications for 89 Sr-dichloride therapy are alternative or supplemental therapy for pain palliation for symptomatic osteoblastic metastasis, usually confirmed by bone scintigraphy, which leads to less opiate use and improved quality of life [25, 26] . The most positive clinical results are seen in patients with prostate, breast, or lung cancer. Promising results have also been reported for small numbers of patients with head and neck, colorectal, or urological cancer [25, 26] Sr-dichloride and other bone-seeking radiopharmaceuticals in terms of response rate for bone pain palliation or toxic effects. Therefore, factors such as availability, cost, clinical preference, and clinical experience will determine the choice of β-emitter. Re is not a calcium analog, 186 Re-HEDP, a chelator of bone-seeking polyphosphonates, localizes into bones by binding to hydroxyapatite crystals, forming hydroxide bridges via hydrolysis reactions. Approximately 70% of intravenously injected activity is excreted in the urine within 24 h. Clinical studies using 186 Re-HEDP were performed in patients mainly with CRPC or breast cancer [36] [37] [38] [39] [40] . Overall response rates for pain palliation were between 38% and 82% with 186 Re-HEDP doses of 1295 MBq to 1406 MBq. Typically, a pain response occurred 1-3 weeks after injection with a duration of 5-12 months. There is no definite relationship between dose and pain response [41] . Similar to 89 Sr-dichloride, a transient rise in pain intensity occurs 5 days after treatment with a duration of 2-10 days and is not related to overall pain response. The main side effects are hematological such as thrombocytopenia and are mild and reversible. Two placebocontrolled studies reported a significant reduction in the pain index in the 186 Re-HEDP group compared with the placebo group [42, 43] . However, due to the lack of well-designed phase III studies, 186 Re-HEDP has not been officially approved by the US FDA or Korean MFDS. However, 186 Re-HEDP is clinically available in Europe. 
Sm-EDTMP
Although Sm, similar to 186 Re, is not a calcium analog, 153 Sm-EDTMP is a chelator of bone-seeking polyphosphonates and localizes into bone after intravenous injection (37 MBq/kg is the recommended dose) with a higher affinity for metastatic than normal bones. No specific localization occurs outside the skeleton. Free 153 Sm-EDTMP is excreted mainly via urine within 8 h. Pain relief occurs in 60-85% of patients within 1 week of administration, with a definite dose-response relationship. Transient myelosuppression is the most common side effect [44] . In several phase II/III clinical trials, 153 Sm-EDTMP has shown significant efficacy for bone pain palliation in patients with various types of cancer including breast cancer, lung cancer, osteosarcoma, and prostate cancer [45] [46] [47] Ra-dichloride can cause lethal double-strand DNA breaks in adjacent tumor cells in bones. These breaks can result in a highly localized antitumor effect in targeted areas containing metastatic cancer cells. In addition, the shorter range of α-particles (< 100 μm, less than 10 cell diameters) compared to β-particles contributes to lower toxicity in normal bone marrow.
In 1915-1916, radioactive radium was first used for cancer therapy as a form of external radiation therapy or brachytherapy [48] . Based on promising results from experimental skeletal metastases models [49] , results of the first phase I clinical trial were reported in 2005 for patients with breast or prostate cancer [50] . Results for the first phase II clinical trial were reported in 2007 for patients with CRPC [51] . Based on the good results obtained in the phase II trial, a phase III ALSYMPCA trial was performed, and the results were published in 2013 [52] . This randomized double-blind placebocontrolled study on the use of 223 Ra in 921 CRPC patients with symptomatic bone metastases, no visceral metastases, and previous use of docetaxel compared with placebo showed significant improvements in overall survival, time to first symptomatic skeletal event, and biochemical response. In May 2013, the US FDA approved 
Biodistribution, Pharmacokinetics, and Radiation Safety
After intravenous injection, 223 Ra-dichloride is rapidly cleared from the blood, with less than 1% activity remaining in plasma at 24 h [50, 53] . Excretion is mainly through the gastrointestinal tract. Early excretion is by the small bowel, and subsequent fecal excretion with about 52% of administered activity occurs at 24 h. There is no evidence of hepatobiliary clearance. Urinary excretion is small at less than 5% of injected activity.
The calculated absorbed dose based on the International Commission on Radiological Protection Publications 67 and 103 is highest in the bone endosteum (cortical bone), followed by the red marrow, liver, colon, and large intestine [54] . 223 Ra-dichloride has the highest bone surface to red bone marrow dose ratio, followed by 153 Sm-EDTMP and 89 Sr-dichloride [55] . Dose rates from patients who have undergone 223 Radichloride therapy at 50, 100, or 200 kBq/kg of body weight have been reported to be less than 2 μSv/h per MBq on contact and 0.02 μSv/h per MBq on average at 1 m following injection [56] . Therefore, patients who undergo 223 Ra-dichloride therapy do not need to be hospitalized.
Toxicity
Hematological toxicity from 223 Ra-dichloride is relatively mild compared with other bone-seeking β-emitters. No clinical trials have found clinically meaningful differences in the frequency of grade 3/4/5 adverse events between patients treated with 223 Ra-dichloride and those treated with a placebo [50, 51] . Because bone marrow suppression varies widely, serum blood cell counts of patients must be evaluated at baseline and before each administration of the radiopharmaceutical. The recommended dosing schedule for 223 Ra-dichloride is one intravenous injection every 4 weeks for 6 months (total six injections) at 50 kBq/kg body weight activity per injection. Before the first administration, the absolute neutrophil count (ANC) should be ≥ 1.5 × 10 9 /l, platelet count ≥ 100 × 10 9 /l, and hemoglobin ≥ 10.0 g/dl. Before subsequent administrations, ANC should be ≥ 1.0 × 10 9 /l and platelet count ≥ 50 × 10 9 /l. If no recovery occurs within 6-8 weeks after final administration of 223 Ra-dichloride, despite standard supportive care, further treatment should be continued only after a careful riskbenefit evaluation [57] . In general, 223 Ra-dichloride is not indicated for patients who are pregnant, are eligible for docetaxel treatment, have visceral or brain metastasis, or have imminent or established spinal cord compression. 223 Ra-dichloride should be used carefully in patients with recent or ongoing cytotoxic chemotherapy, prior hemibody external radiotherapy, lymphadenopathy exceeding a 3-cm short-axis diameter, any size pelvic lymphadenopathy thought to contribute to concurrent hydronephrosis, Crohn's disease, ulcerative colitis, myelodysplastic or myeloproliferative syndromes, unstable fracture, or jaw osteonecrosis.
Very common side effects (≥ 10%) include thrombocytopenia, nausea, vomiting, and diarrhea. Common side effects (≥ 1%) include neutropenia, pancytopenia, leucocytopenia, and injection site reaction. Uncommon side effects (< 1%) include lymphocytopenia [57] . The occurrence of a second primary cancer related to this therapy after 3 years of followup has not been reported.
Clinical Effectiveness
Most clinical studies of 223 Ra-dichloride have been performed in patients with metastatic CRPC. Metastatic CRPC is known to have a poor prognosis, with a 5-year survival rate of about 25% and a 40-month median survival. Standard therapy for CRPC with bone metastasis is docetaxel-based chemotherapy. However, if the treatment fails, no alternative therapy exists. The pivotal phase III ALSYMPCA randomized double-blind placebo-controlled trial was based on promising phase I and II studies [49] [50] [51] . The trial studied use of 223 Ra-dichloride in 921 patients with metastatic CRPC with symptomatic bone metastasis, previous use of analgesics or recent radiotherapy to bones, and no visceral metastasis and found significant improvements in median overall survival (14.9 months in the 223 Ra-dichloride group vs. 11.3 months in the placebo group, hazard ratio = 0.70, p < 0.001) and median time to the first symptomatic skeletal event (15.6 months in the 223 Ra-dichloride group vs. 9.8 months in the placebo group, hazard ratio = 0.66, p < 0.001) [52] . In subgroup analyses, the 223 Ra-dichloride group had significantly better survival than the placebo group irrespective of baseline serum alkaline phosphatase (ALP) level, previous docetaxel use, current bisphosphonate use, or previous opioid use. For secondary end points, the 223 Ra-dichloride group had significantly longer median time to increased total ALP, longer median time to increased serum prostate-specific antigen, more patients with ≥ 30% reduction in total ALP response, and more patients with normalization of total ALP than the placebo group. No significant differences were seen in frequency of hematological or nonhematological adverse events between the two groups.
Issues for Discussion
223 Ra-dichloride therapy has several important caveats. First, it is expensive, at approximately 10,000 USD (about 8,000,000 KRW in Korea) per injection. In the standard protocol, six injections are necessary. Although Medicare in the US covers 223 Ra-dichloride therapy if reasonable and necessary, this treatment is not covered by the National Health Insurance in Korea. Considering the variable prices and treatment durations for bone metastasis, performing a cost-benefit analysis for 223 Ra-dichloride therapy is difficult. In the US, six cycles of treatment with 223 Ra-dichloride were found to cost 69,000 USD. Although this is more than docetaxel (approximately 14,500 USD for a course of 10 cycles plus ancillary costs), it is similar to enzalutamide (approximately 60,000 USD for 8 months of treatment) and costs less than a course of sipuleucel-T (93,000 USD) [58] . The ALSYMPCA trial observed a 24% reduction in the annual number of hospitalizations and 6.5 fewer hospitalization days per patient per year in patients treated with 223 Ra-dichloride. This is probably due to a delay in the occurrence of symptomatic skeletal events [52, 59] [60] .
Future Directions and Conclusion
Radionuclide therapy using bone-seeking radiopharmaceuticals is a safe and effective therapy for bone pain palliation in various kinds of cancer with bone metastasis, mainly prostate cancer. Although it is controversial whether β-emitters improve survival, the combination of radionuclide therapy with other therapies such as chemotherapy or external radiation therapy has the potential to improve patient survival. This possibility deserves further well-designed phase III trials. Radionuclide therapy using the α-emitter Ra-223 is a safe and effective therapy for CRPC with bone metastasis and can result in bone pain palliation and survival gains. Further clinical trials are needed to assess the utility of Ra-223 in other cancer types.
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